Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
71%(5 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
3
33%
Ph phase_2
4
44%
Ph phase_3
2
22%

Phase Distribution

3

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(2)

Detailed Status

Completed7
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 24 (44.4%)
Phase 32 (22.2%)

Trials by Status

completed778%
withdrawn111%
terminated111%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_2

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

NCT05155085
completedphase_2

A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria

NCT03436797
completedphase_2

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

NCT03664960
completedphase_2

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

NCT03496571
completedphase_3

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

NCT04856891
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05155085Phase 2

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

Terminated
NCT03436797Phase 2

A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria

Completed
NCT03664960Phase 2

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Completed
NCT03496571Phase 2

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

Completed
NCT04856891Phase 3

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

Completed
NCT05152563Phase 3

A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Withdrawn
NCT03379311Phase 1

A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis

Completed
NCT02808793Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

Completed
NCT02859701Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9